You’re using a public version of DrugChatter with 1 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

What are the criteria for lacosamide approvals?



Lacosamide is a prescription medication used to treat partial-onset seizures in adults and children. The criteria for lacosamide approvals vary depending on the health insurance plan. However, there are some general criteria that are commonly used across different plans.

According to Drug Patent Watch [1], lacosamide is approved by the FDA for the treatment of partial-onset seizures in patients with epilepsy who are 17 years of age and older. The drug is available in tablet and injection form, and it works by reducing the activity of certain brain cells that cause seizures.

The United Healthcare Prior Authorization Notification [2] states that prior authorization is required for lacosamide tablets and injection. The criteria for approval include a diagnosis of partial-onset seizures, failure of at least two other antiepileptic drugs, and the absence of a contraindication to lacosamide therapy. The notification also specifies that the maximum dose of lacosamide should not exceed 400 mg/day.

Similarly, the Superior HealthPlan Pharmacy Policy [3] states that prior authorization is required for lacosamide tablets and injection. The criteria for approval include a diagnosis of partial-onset seizures, failure of at least two other antiepileptic drugs, and the absence of a contraindication to lacosamide therapy. The policy also specifies that the maximum dose of lacosamide should not exceed 400 mg/day.

In conclusion, the criteria for lacosamide approvals generally include a diagnosis of partial-onset seizures, failure of at least two other antiepileptic drugs, and the absence of a contraindication to lacosamide therapy. The maximum dose of lacosamide should not exceed 400 mg/day. However, it is important to note that the specific criteria may vary depending on the health insurance plan.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LACOSAMIDE
[2] https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Vimpat.pdf
[3] https://www.superiorhealthplan.com/content/dam/centene/Superior/policies/pharmacy-policies/CP.PMN.155-09012021.pdf



Follow-up:   What are the lacosamide dosage guidelines? How does lacosamide interact with other medications? Are there any reported side effects of lacosamide?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2024. All rights reserved.